Obese mice treated with this molecule exhibit improved glucose tolerance and decreased hepatic steatosis accompanied by a reduction of the metabolic inflammation phenotype, indicating GPR120 is an attractive potential target for the treatment of obesity-associated metabolic disorders. Here, FFAR4 is linked to obesity disorder.